Last reviewed · How we verify
NCT06593847: ETC2
Multisite Virtual Reality Intervention for Speech Anxiety
NA trial testing Single-session VR exposure intervention in Public Speaking in 1,542 participants. Completed in 23 July 2025.
23 July 2025
Quick facts
| Lead sponsor | Boston University Charles River Campus |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,542 |
| Start date | 8 October 2024 |
| Primary completion | 23 July 2025 |
| Estimated completion | 23 July 2025 |
| Sites | 13 locations across Netherlands, Germany, Australia, China, United States |
Drugs / interventions tested
- Single-session VR exposure intervention
Conditions studied
- Public Speaking — all drugs for Public Speaking →
- Speech Anxiety — all drugs for Speech Anxiety →
Sponsor
Boston University Charles River Campus
Who can join
Adults 18 to 70, any sex, with Public Speaking or Speech Anxiety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted for by examination of baseline levels of self-efficacy, hope, and optimism.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Moderating Role of State and Trait Positive Affect in Virtual Reality Exposure for Public Speaking Anxiety: Protocol for a Multisite Experimental Study
Otto M, Long L, Papini S, Culver T, et al · · 2025
Verify or expand the search:
- PubMed search for NCT06593847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Boston University Charles River Campus trials
Trials by the same sponsor.
- NCT07461584 — Memory Enhancement in Aging With Optimal Dosing · EARLY_PHASE1 · not yet recruiting
- NCT07208318 — Restructuring the Alpha-Gamma Code in Aging Vision · EARLY_PHASE1 · not yet recruiting
- NCT06182241 — Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South · NA · not yet recruiting
- NCT07158801 — Project EMPOWER-OCD · Phase 1 · not yet recruiting
- NCT05624931 — Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06593847 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston University Charles River Campus
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06593847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing